Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Add shares to your
quickpicks to
display them here!

PureTech (PRTC)

Price 202.00p on 01-03-2024 at 18:00:50
Change 5.00p 2.54%
Buy 204.00p
Sell 203.00p
Buy / Sell PRTC Shares
Last Trade: Unknown 60,000.00 at 202.00p
Day's Volume: 409,020
Last Close: 202.00p
Open: 200.00p
Day's Range 195.00p - 203.50p
52wk Range: 139.00p - 242.00p
Market Capitalisation: £545m
VWAP: 200.4501p
Shares in Issue: 270m

Recent Trades History PureTech (PRTC)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 60,000 202.00p Currency Conversion
OTC Trade
18:00:32 - 01-Mar-24
Unknown* 7,641 197.092p Currency Conversion
OTC Trade
17:35:43 - 01-Mar-24
Unknown* 663 202.324p Currency Conversion
OTC Trade
17:29:51 - 01-Mar-24
Unknown* 3,835 199.492p Currency Conversion
OTC Trade
17:27:04 - 01-Mar-24
Unknown* 13,273 201.999p Currency Conversion
OTC Trade
17:27:04 - 01-Mar-24
Unknown* 173 199.80p Currency Conversion
OTC Trade
17:08:52 - 01-Mar-24
Unknown* 7,070 201.411p Currency Conversion
OTC Trade
17:08:51 - 01-Mar-24
Unknown* 490 201.247p Currency Conversion
OTC Trade
17:08:15 - 01-Mar-24
Sell* 151,779 202.00p Uncrossing Trade
16:35:02 - 01-Mar-24
Unknown* 785 204.00p SI Trade
Currency Conversion
16:29:49 - 01-Mar-24

Share Price History for PureTech

Time period:
Date Open High Low Close Volume

Share News for PureTech

PureTech notes positive results from Shionogi's EndeavorRx ADHD trial

27th Feb 2024 11:28

(Alliance News) - PureTech Health PLC on Tuesday noted that its founded entity, Akili Inc, has announced positive results from a phase 3 clinical trial of EndeavorRx for children with attention deficit hyperactivity disorder in Japan. Read More

PureTech makes strong progress, expects "multiple catalysts" next year

20th Dec 2023 09:53

(Alliance News) - PureTech Health PLC on Wednesday said it made "strong strategic and clinical progress" in 2023, and predicted "a productive and exciting" tear to come. Read More

TRADING UPDATES: N4 launches investor hub; Capricorn production falls

1st Dec 2023 14:29

(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News: Read More

IN BRIEF: PureTech hails schizophrenia trial results for Karuna drug

17th Nov 2023 09:44

PureTech Health PLC - Boston, Massachusetts-based FTSE 250 biotechnology company - Founded entity Karuna Therapeutics reports "positive results" from Phase 1b trial evaluating the effects of xanomeline-trospium, brand name KarXT, on 24-hour ambulatory blood pressure in adults with schizophrenia. Karuna says KarXT does not cause clinically meaningful blood pressure increases, with an average change from baseline at week eight of minus 0.59 mmHg or millimetre of mercury. Other vital signs like average diastolic blood pressure and heart rate were consistent with previous KarXT trials in schizophrenia. Adds that KarXT was generally well-tolerated, and side effects remained consistent with prior trials under the Emergent programme. Karuna in late September announced its application to the US Food & Drug Administration for approval of KarXT to treat schizophrenia; if successful, it will be PureTech's third therapeutic candidate to gain FDA approval. KarXT is also in development to treat psychosis associated with Alzheimer's disease. Read More

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

17th Nov 2023 07:58

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell. Read More

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered